Viewing Company CRH Medical Corp. | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

CRH Medical Corp. Stock Symbol: CRH-T

Last Price Recorded: $4.2300 on 2017-07-27

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-07-26 COMMENT Bruce Campbell (2)

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.


Price:
$4.260
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
Unknown
2017-07-24 COMMENT Matt Kacur

News items make it difficult for anyone to analyze.  They have one of the best returns of capital.  The rules have changed.  Probably it is okay.  Usually the rule changes sound more threatening than they really are.


Price:
$4.500
Subject:
NORTH AMERICAN
Bias:
SELECTIVE
Owned:
Unknown
2017-07-17 WATCH Brendan Caldwell

He has no price target.  It is another great Canadian healthcare stock that got hammered a short while ago.  The reason for the most recent decline is that Central Medical Services has changed how they code some services.  This company should eventually be at higher prices, but he wants to see the dust settle.


Price:
$4.670
Subject:
CANADIAN VALUE
Bias:
SELECTIVE
Owned:
No
2017-07-13 HOLD Jerome Hass

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on.  He thinks the short thesis is a little overplayed. 


Price:
$6.620
Subject:
CANADIAN MID-LARGE & SHORT-LONG STRATEGIES
Bias:
Bullish on Canadian Equities
Owned:
Unknown
2017-07-10 COMMENT Jason Del Vicario

When a Short report came out, this dropped about 30%. Had sold about half his position in the $11 range to take some risk off the table. The stock is now close to the level, where if it breaches it, he will be selling his position. Believes their business is strong. He likes the company, but is just a little worried about it technically right now. On a P/E ratio, they seem really expensive. They have a nice ROE.


Price:
$6.750
Subject:
NORTH AMERICAN (GROWTH)
Bias:
CAUTIOUS
Owned:
Yes
2017-06-30 WATCH Hap (Robert) Sneddon FCSI

Going ahead 3 or 4 years, he is pretty comfortable that the whole medical space will be higher. We are in a secular bull market with healthcare. It had a big spike down this year, but the range we are in now has provided some support. There was a low of $6.84 in May, but doesn’t think it is going back there. It seems to be basing around $7.23-$7.38. Look for this to break out at around $7.65-$7.73, which will tell him it is really getting some legs. It is probably going to base here for a while.


Price:
$7.380
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
BULLISH
Owned:
Unknown
2017-06-22 PAST TOP PICK Bruce Campbell (2)

(Top Pick Jun 30/16, Up 52%) It was almost $12 at one point and was really stretched, then a short report came out, all before he bought it.  He likes the business and feels they will continue to do well.  They have great cash flow for acquisitions. 


Price:
$7.820
Subject:
CANADIAN & CANNABIS STOCKS
Bias:
BULLISH
Owned:
Yes
2017-05-25 COMMENT Peter Imhof

This got up to $11-$12, where he thought it was a little ahead of itself. Markets were jittery and someone came out with a Short report, so a lot of Shorts piled on and the stock came off quite a bit. At the current value of around $8, it looks half decent. He is comfortable with management.


Price:
$8.050
Subject:
SMALL CAPS
Bias:
BULLISH
Owned:
Yes
2017-05-05 COMMENT Jerome Hass

A recent Short report made some interesting points. Although he doesn’t like serial acquisitors, he likes that this company is very focused on what they are doing. When they make an acquisition, they typically get 50%-51% of the business, so they consolidate it. Their revenue numbers are generally growing much faster than their earnings because they have to take out the minority interests. They are recognizing 100% of the revenues, but effectively are only getting 51% of the earnings. That was one of the thrusts of the Short report. The other was that they were being paid to use an MD to administer their deep sedation (used in colonoscopies), but using specially trained professional nurses instead. A decent company, he is just not sold on it yet.


Price:
$8.510
Subject:
CANADIAN MID-CAPS & LONG/SHORT STRATEGIES
Bias:
UNKNOWN
Owned:
No
2017-04-26 COMMENT Robert McWhirter

Ranks 222 out of 723 stocks in his model. If putting new money to work, you would typically look for something higher up in the rank. Currently trading at $9.12, and the overall earnings estimates for 2017 is $.28, giving a reasonable PE multiple. ROE of 25% looks attractive. Next year’s earnings growth is expected to be 21%, against a 28 PE, giving a PE to growth next year of 1.3X. It looks a bit expensive.


Price:
$8.990
Subject:
CANADIAN DIVIDEND & GROWTH
Bias:
OPTIMISTIC
Owned:
Unknown
2017-04-26 COMMENT Bruce Campbell (2)

Just reported and beat street expectations. Revenue was expected to be $21.3 million, and came in at $22.5 million. Total operating earnings was up 63%. They continue to make acquisitions, and have great cash flow. Last week, there was a Short report which scared a lot of people, probably because of the valuation. He likes it here.


Price:
$8.990
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:
Yes
2017-04-11 PARTIAL BUY Ryan Modesto

He likes this. A bit of a rollup. They are buying portions of medical practices in the US, and then are installing anaesthesiologists to do anaesthetic services. The valuation is running up a bit, but if you are looking at Enterprise Value to a bit of multiple, it is about 16X. Still a bit pricey, but nothing too crazy. He likes that they are offering liquidity to doctors, who are starting to age and want to get some cash out of the business. Good insider ownership. Worth owning, but you might want to average into it.


Price:
$12.030
Subject:
CANADIAN SMALL & MIDCAPS
Bias:
UNKNOWN
Owned:
No
2017-04-03 BUY Keith Richards

It is your classic breakout.  It is just pulling back now and then will continue back up.  It is a very bullish chart.


Price:
$10.920
Subject:
TECHNICAL ANALYSIS
Bias:
BULLISH on ENERGY
Owned:
Unknown
2017-03-13 COMMENT Matt Kacur

A very strong company. ROC is astoundingly high. The valuation looks really good. From a pure, financial Return on Capital and valuation perspective, this looks really good.


Price:
$10.720
Subject:
NORTH AMERICAN
Bias:
CAUTIOUS
Owned:
Unknown
2017-03-10 BUY on WEAKNESS Bruce Campbell (2)

Doesn’t think they will need to do an equity raise unless they do a big acquisition. They roughly have the cash flow they need to make an acquisition each quarter, of about the same size that they have been doing. His one caution is that the valuation is very high. Be prepared that an analyst could come out and say it is fully valued, resulting in the stock pulling back. If it did, it would probably be a great buying opportunity. Also, if they did an equity offering, that would be another great time to add to your holdings.


Price:
$10.380
Subject:
CANADIAN & CANNABIS STOCKS
Bias:
OPTIMISTIC
Owned:
Unknown
Showing 1 to 15 of 69 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.